眼科ドラッグデリバリーの世界市場

眼科ドラッグデリバリーの世界市場は2030年までに943億米ドルに達する見込み

2024年に731億米ドルと推定される眼科ドラッグデリバリーの世界市場は、2024年から2030年にかけてCAGR 4.3%で成長し、2030年には943億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである局所技術は、CAGR 5.8%を記録し、分析期間終了時には352億米ドルに達すると予想されます。眼インサート技術セグメントの成長率は、分析期間中CAGR 3.2%と推定されます。

米国市場は推定199億米ドル、中国はCAGR8.2％で成長予測

米国の眼科ドラッグデリバリー市場は2024年に199億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに197億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.4%と予測されています。欧州では、ドイツがCAGR 2.5%で成長すると予測されています。

世界の眼科ドラッグデリバリー市場- 主要動向と促進要因のまとめ

眼科ドラッグデリバリーが視力障害治療のパラダイムシフトを起こす理由とは？

眼科ドラッグデリバリーは眼科領域において急速に発展している領域であり、解剖学的障壁を克服し、治療濃度の持続性を維持しながら、眼内の標的組織に治療薬を直接送達する必要性に後押しされています。角膜、血液-房水関門、血液-網膜関門のような保護関門を含む眼球の独特な構造により、従来の全身または局所ドラッグデリバリーは後眼部疾患の治療にはほとんど効果がないです。このため、局在化、標的化、徐放性のドラッグデリバリープラットフォームの技術革新が必要となっています。

加齢黄斑変性症（AMD）、糖尿病性網膜症、緑内障、ぶどう膜炎などの眼疾患の世界の増加により、効果的で患者に適合したデリバリーシステムに対するかつてない需要が生じています。点眼薬や硝子体内注射といった従来の投与経路は、生物学的利用能の低さ、作用時間の短さ、患者の服薬アドヒアランスの問題によって制限されています。インプラント、ナノキャリア、in situ形成ゲル、マイクロニードルアレイなどの新技術は、薬剤の浸透性を高め、放出プロファイルを拡張し、侵襲性を最小限に抑えることで、これらの限界に対処しています。人口の高齢化や糖尿病罹患率の上昇に伴い、視力を脅かす疾患がますます蔓延する中、眼科ドラッグデリバリーは眼科医療の重要な柱となりつつあります。

眼科ドラッグデリバリーの革新は、眼科における有効性、安全性、患者のコンプライアンスをどのように向上させているか？

最先端のドラッグデリバリープラットフォームは、生分解性インプラント（デキサメタゾン硝子体内インプラントなど）、再充填可能なリザーバー、ナノ粒子をベースとしたキャリアなど、様々な技術により、より長い治療期間と組織特異性を実現しています。これらのシステムは、数週間から数ヵ月にわたって薬剤を放出し、硝子体内注射の頻度を減らすことで、患者のコンプライアンスと臨床転帰を改善します。徐放性コルチコステロイドや抗VEGF剤は現在、慢性網膜疾患の管理において、より少ない介入回数で日常的に使用されています。

局所ナノミセル、リポソーム、デンドリマー、ハイドロゲルは、注射を必要とせずに前眼部や後眼部に投与できるように開発されています。温度、pH、酵素のトリガーに反応するin situ形成ゲルや眼球インサートは、薬物の滞留時間と治療反応を改善しています。薬物放出を制御できる埋め込み型マイクロポンプや電子デバイスも開発中で、デジタル治療と眼科ドラッグデリバリーの融合を象徴しています。これらの技術は、眼科治療薬の薬物動態学的・薬力学的状況を再定義し、正確でプログラム可能な、患者に優しい治療パラダイムを可能にしつつあります。

高度な眼デリバリーソリューションの需要を牽引している臨床適応症と地域ヘルスケアシステムは？

AMD、糖尿病黄斑浮腫（DME）、網膜静脈閉塞症などの慢性後眼部疾患は、硝子体内ドラッグデリバリーシステムや徐放性ドラッグデリバリーシステムの需要を牽引する最大の要因です。緑内障治療もまた、服薬アドヒアランスと眼圧コントロールを改善するために、埋め込み型デバイスや放出制御機構へとシフトしています。小児眼科と老年眼科は、眼科ドラッグデリバリーの課題とコンプライアンスの問題が特に深刻な成長分野であり、1日1回投与製剤やデポ製剤の必要性が強調されています。

北米と欧州は、薬事承認、市販製品の入手可能性、眼科専門医療インフラの面でリードしています。米国市場ではFDA承認のインプラントやナノ製剤の急速な普及が見られ、欧州市場では集中的な償還と高いアンメットニーズの恩恵を受けています。アジア太平洋地域は、人口の高齢化、糖尿病人口の増加、政府主導の失明予防イニシアチブを背景に、日本、インド、中国を中心に高い需要の伸びが見られます。ラテンアメリカと中東は、先進的なドラッグデリバリープラットフォームをますます取り入れるようになっている官民パートナーシップや眼科医療NGOプログラムを通じてアクセスを拡大しています。

眼科ドラッグデリバリー市場の長期的成長と分野横断的イノベーションの原動力は？

眼科ドラッグデリバリー市場の成長の原動力は、視力喪失の有病率の上昇、治療負担軽減の必要性、製薬工学、バイオマテリアル、ナノテクノロジーの進歩です。製薬会社が患者中心のイノベーションを通じて眼科ポートフォリオを差別化しようと競争する中、医薬品開発者、デバイスメーカー、材料科学者のコラボレーションが画期的な治療法を生み出しています。バイオシミラー、遺伝子治療、二剤併用プラットフォームは、副作用を最小限に抑えながら眼科バイオアベイラビリティを最適化する眼科ドラッグデリバリーシステムと統合されつつあります。

眼科ドラッグデリバリーを補完し、治療反応を追跡するために、人工知能、遠隔モニタリング、スマート眼科デバイスが研究されています。希少眼科用医薬品に対する規制上の優遇措置や、革新的なデリバリー・プラットフォームに対するファスト・トラック指定により、市場参入が加速しています。医薬品、生物製剤、デバイスの境界が曖昧になるにつれ、眼科ドラッグデリバリーは眼科におけるプレシジョン・メディシンの焦点となりつつあります。

セグメント

技術（外用剤、眼内挿入剤、眼内インプラント、眼内ゲル、その他の技術）、製剤タイプ（軟膏、溶液、乳剤、懸濁液、その他の製剤タイプ）、適応疾患（緑内障、糖尿病網膜症、ドライアイ症候群、加齢黄斑変性、その他の適応疾患）、エンドユーザー（病院、眼科クリニック、その他のエンドユーザー）

調査対象企業の例（注目の合計42社）

• AbbVie Inc.
• Aciont Inc.
• Alcon
• Alimera Sciences, Inc.
• Allergan（an AbbVie company）
• Bausch Health Companies Inc.
• Clearside Biomedical, Inc.
• EyeGate Pharmaceuticals, Inc.
• Eyenovia, Inc.
• EyePoint Pharmaceuticals, Inc.
• Genentech, Inc.
• Graybug Vision, Inc.
• Iris Pharma
• Johnson & Johnson Vision Care, Inc.
• Kiora Pharmaceuticals, Inc.
• Nicox S.A.
• Novaliq GmbH
• Novartis AG
• Ocular Therapeutix, Inc.
• Oculis SA

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Ocular Drug Delivery Market to Reach US$94.3 Billion by 2030

The global market for Ocular Drug Delivery estimated at US$73.1 Billion in the year 2024, is expected to reach US$94.3 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Topical Technology, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$35.2 Billion by the end of the analysis period. Growth in the Ocular Insert Technology segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.9 Billion While China is Forecast to Grow at 8.2% CAGR

The Ocular Drug Delivery market in the U.S. is estimated at US$19.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$19.7 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Ocular Drug Delivery Market - Key Trends & Drivers Summarized

Why Is Ocular Drug Delivery Undergoing a Paradigm Shift in Treating Vision-Threatening Disorders?

Ocular drug delivery is a rapidly evolving domain in ophthalmology, driven by the need to deliver therapeutic agents directly to target tissues within the eye while overcoming anatomical barriers and maintaining sustained therapeutic concentrations. The unique structure of the eye-including protective barriers like the cornea, blood-aqueous barrier, and blood-retinal barrier-makes conventional systemic or topical drug delivery largely ineffective for treating posterior segment diseases. This has necessitated innovation in localized, targeted, and extended-release drug delivery platforms.

The rising global burden of ocular diseases such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and uveitis is creating unprecedented demand for effective and patient-compliant delivery systems. Traditional routes such as eye drops and intravitreal injections are limited by poor bioavailability, short duration of action, and patient adherence issues. Emerging technologies, including implants, nano-carriers, in situ forming gels, and microneedle arrays, are addressing these limitations by enhancing drug penetration, extending release profiles, and minimizing invasiveness. As sight-threatening conditions become more prevalent with aging populations and rising diabetes rates, ocular drug delivery is becoming a critical pillar of ophthalmic care.

How Are Drug Delivery Innovations Improving Efficacy, Safety, and Patient Compliance in Ophthalmology?

Cutting-edge ocular drug delivery platforms are achieving longer therapeutic duration and tissue specificity through a range of technologies, including biodegradable implants (e.g., dexamethasone intravitreal implants), refillable reservoirs, and nanoparticle-based carriers. These systems release drugs over weeks to months, reducing the frequency of intravitreal injections and thereby improving patient compliance and clinical outcomes. Sustained-release corticosteroids and anti-VEGF agents are now routinely used in managing chronic retinal diseases with fewer interventions.

Topical nanomicelles, liposomes, dendrimers, and hydrogels are being developed to enable anterior and posterior segment delivery without the need for injections. In situ-forming gels and ocular inserts that respond to temperature, pH, or enzymatic triggers are improving drug residence time and therapeutic response. Implantable micro-pumps and electronic devices capable of controlled drug release are also in development, representing the convergence of digital therapeutics with pharmaceutical delivery. These technologies are redefining the pharmacokinetic and pharmacodynamic landscape of ocular therapeutics, enabling precise, programmable, and patient-friendly treatment paradigms.

Which Clinical Indications and Regional Healthcare Systems Are Driving Demand for Advanced Ocular Delivery Solutions?

Chronic posterior segment disorders-such as AMD, diabetic macular edema (DME), and retinal vein occlusion-are the largest drivers of demand for intravitreal and sustained-release drug delivery systems. Glaucoma treatment is also shifting toward implantable devices and controlled-release mechanisms to improve adherence and intraocular pressure control. Pediatric and geriatric ophthalmology are additional growth areas where drug delivery challenges and compliance issues are particularly acute, highlighting the need for once-daily or depot formulations.

North America and Europe lead in terms of regulatory approvals, commercial product availability, and specialist ophthalmic care infrastructure. The U.S. market has witnessed rapid adoption of FDA-approved implants and nanoformulations, while the European market benefits from centralized reimbursement and high unmet need. Asia-Pacific is witnessing high demand growth, particularly in Japan, India, and China, due to aging populations, diabetic demographics, and government-led blindness prevention initiatives. Latin America and the Middle East are expanding access through public-private partnerships and eye-care NGO programs that increasingly incorporate advanced drug delivery platforms.

What Is Driving Long-Term Growth and Cross-Disciplinary Innovation in the Ocular Drug Delivery Market?

The growth in the ocular drug delivery market is driven by rising vision loss prevalence, treatment burden reduction imperatives, and advances in pharmaceutical engineering, biomaterials, and nanotechnology. As pharmaceutical companies race to differentiate ophthalmic portfolios through patient-centric innovations, collaboration between drug developers, device manufacturers, and materials scientists is yielding transformative therapies. Biosimilars, gene therapies, and dual-drug platforms are being integrated with delivery systems that optimize ocular bioavailability while minimizing side effects.

Artificial intelligence, remote monitoring, and smart ophthalmic devices are being explored to complement drug delivery and track therapeutic response. Regulatory incentives for orphan ophthalmic drugs and fast-track designations for innovative delivery platforms are accelerating market entry. As the boundaries between pharmaceuticals, biologics, and devices blur, ocular drug delivery is becoming a focal point of precision medicine in ophthalmology-promising sight preservation, procedural simplicity, and life-changing outcomes for millions affected by chronic eye conditions.

SCOPE OF STUDY:

The report analyzes the Ocular Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Topical, Ocular Insert, Intraocular Implants, In-Situ Gel, Other Technologies); Formulation Type (Ointment, Solution, Emulsion, Suspension, Other Formulation Types); Disease Indication (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration, Other Disease Indications); End-User (Hospitals, Ophthalmic Clinics, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• AbbVie Inc.
• Aciont Inc.
• Alcon
• Alimera Sciences, Inc.
• Allergan (an AbbVie company)
• Bausch Health Companies Inc.
• Clearside Biomedical, Inc.
• EyeGate Pharmaceuticals, Inc.
• Eyenovia, Inc.
• EyePoint Pharmaceuticals, Inc.
• Genentech, Inc.
• Graybug Vision, Inc.
• Iris Pharma
• Johnson & Johnson Vision Care, Inc.
• Kiora Pharmaceuticals, Inc.
• Nicox S.A.
• Novaliq GmbH
• Novartis AG
• Ocular Therapeutix, Inc.
• Oculis SA

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Ocular Drug Delivery - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rise in Chronic Eye Disorders Such as AMD and Glaucoma Drives Demand for Advanced Drug Delivery Systems
  • Innovation in Sustained-Release Implants Strengthens Business Case for Long-Term Ocular Therapies
  • Growth in Diabetic Retinopathy Incidence Spurs Adoption of Intravitreal Drug Delivery Platforms
  • Surge in Biologic and Biosimilar Launches Expands Pipeline of Ophthalmic Drug Candidates
  • Regulatory Approvals of Minimally Invasive Delivery Devices Propel Market Commercialization
  • Emergence of Nanoformulations and Microparticles Throws the Spotlight on Precision Drug Targeting
  • Increased Investment in Gene Therapy and Ocular mRNA Delivery Enhances Pipeline Innovation
  • Growing Focus on Patient Adherence Drives Development of Depot and Injectable Solutions
  • Integration of Smart Contact Lenses and Wearables Supports Real-Time Drug Delivery Monitoring
  • Advancements in Mucoadhesive and Gel-Based Formulations Expand Topical Treatment Effectiveness
  • Global Expansion of Ophthalmology Clinics in Emerging Markets Sustains Access to Advanced Therapies
  • Rising Use of Biodegradable Polymers Enhances Ocular Implant Acceptance and Biocompatibility
  • Clinical Emphasis on Retinal Disease Management Accelerates Adoption of Posterior Segment Delivery Tools
  • Increased Preference for Office-Based Intravitreal Procedures Enhances Outpatient Market Growth
  • Collaborations Between Pharma and Device Firms Propel Innovation in Combination Products
  • Challenges in Formulating Large-Molecule Drugs for Ocular Use Create R&D Bottlenecks
  • Reimbursement Support for Premium Ophthalmic Devices Strengthens Market Expansion
  • Shortage of Eye Care Professionals in Low-Income Regions Spurs Demand for Self-Administered Delivery Systems
  • Increased Use of Animal Models and AI in Ocular Pharmacokinetics Enhances Preclinical Success
  • Growth in Geriatric Population Globally Sustains Chronic Eye Disease Treatment Demand
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Ocular Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Ocular Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Ocular Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Ocular Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Ocular Insert by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Ocular Insert by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Ocular Insert by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Intraocular Implants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Intraocular Implants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Intraocular Implants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for In-Situ Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for In-Situ Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for In-Situ Gel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Formulation Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Formulation Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Formulation Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Solution by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Emulsion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Emulsion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Emulsion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Suspension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Glaucoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Diabetic Retinopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Diabetic Retinopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Diabetic Retinopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Dry Eye Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Dry Eye Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Dry Eye Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Age Related Macular Degeneration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Age Related Macular Degeneration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Age Related Macular Degeneration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Ophthalmic Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Ophthalmic Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Ophthalmic Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 59: USA Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: USA 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Canada 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• JAPAN
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• CHINA
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 95: China Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• EUROPE
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Ocular Drug Delivery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Ocular Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• FRANCE
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 122: France Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 131: France Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: France Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: France 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• GERMANY
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Germany 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Germany Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Germany 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Italy 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 155: Italy Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Italy Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Italy 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 158: UK Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: UK 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 167: UK Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: UK Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: UK 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Spain 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 179: Spain Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Spain Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Spain 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Russia 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 191: Russia Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Russia Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Russia 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Europe Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Europe 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Ocular Drug Delivery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Asia-Pacific Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Australia 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 230: Australia Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Australia Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Australia 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• INDIA
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 233: India Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: India 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 242: India Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: India Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: India 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: South Korea 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 254: South Korea Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: South Korea Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: South Korea 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Rest of Asia-Pacific Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Rest of Asia-Pacific 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Ocular Drug Delivery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Ocular Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Latin America 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 281: Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Latin America Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Latin America 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Argentina 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 293: Argentina Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Argentina Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Argentina 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Brazil 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 305: Brazil Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Brazil Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Brazil 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Mexico 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 317: Mexico Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Mexico Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Mexico 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Latin America Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Rest of Latin America 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Ocular Drug Delivery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Ocular Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Middle East 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 344: Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Middle East Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Middle East 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Iran 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 356: Iran Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Iran Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Iran 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Israel 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 368: Israel Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Israel Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Israel 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Saudi Arabia Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Saudi Arabia 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: UAE 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 392: UAE Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: UAE Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: UAE 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Middle East Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Rest of Middle East 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030
• AFRICA
  • Ocular Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Ocular Drug Delivery by Technology - Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Ocular Drug Delivery by Technology - Percentage Breakdown of Value Sales for Topical, Ocular Insert, Intraocular Implants, In-Situ Gel and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Ocular Drug Delivery by Formulation Type - Other Formulation Types, Ointment, Solution, Emulsion and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Ocular Drug Delivery by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Ointment, Solution, Emulsion and Suspension for the Years 2015, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Ocular Drug Delivery by Disease Indication - Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Africa 15-Year Perspective for Ocular Drug Delivery by Disease Indication - Percentage Breakdown of Value Sales for Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age Related Macular Degeneration and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 416: Africa Recent Past, Current & Future Analysis for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Africa Historic Review for Ocular Drug Delivery by End-user - Hospitals, Ophthalmic Clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 418: Africa 15-Year Perspective for Ocular Drug Delivery by End-user - Percentage Breakdown of Value Sales for Hospitals, Ophthalmic Clinics and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION